Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isotype selection for antibody-based cancer therapy

6 Nov 2020

Abstract excerpt

The clinical application of monoclonal antibodies (mAbs) has revolutionized the field of cancer therapy, as it has enabled the successful treatment of previously untreatable types of cancer. Different mechanisms play a role in the anti-tumour effect of mAbs. These include blocking of tumour-specific growth factor receptors or of immune modulatory molecules as well as complement and cell-mediated tumour cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33155272
DOI: 10.1111/cei.13545

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isotype selection for antibody-based cancer therapyPMID 33155272Read ↗

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector FunctionsSemantic proximity Read ↗

Antibody Isotypes for Tumor ImmunotherapySemantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

Antibody Structure and Function: The Basis for Engineering TherapeuticsSemantic proximity Read ↗

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-LifeSemantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

Optimizing therapeutic antibody function: progress with Fc domain engineering.Semantic proximity Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

Antibody Fc: Linking Adaptive and Innate ImmunitySemantic proximity Read ↗

Molecular engineering to improve antibodies' anti-lymphoma activity.Semantic proximity Read ↗

Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.Semantic proximity Read ↗

Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.